Experimental peptide targeting a VIP receptor (CHEMBL3884667)
A lab-made peptide designed to act on a receptor involved in gut, nerve, and immune signaling; experimental, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does this peptide preferentially activate the PAC1 receptor rather than the VPAC2 receptor that causes dangerous vasodilation?
If true, this peptide could open a path to treating neurological conditions and inflammatory diseases where VIP-like signals are beneficial, without the cardiovascular toxicity that has blocked VIP from clinical use. Patients with conditions like Parkinson's disease or inflammatory bowel disease could potentially benefit.
Could this peptide help the pancreas release insulin through a receptor that current diabetes medications do not target?
If this peptide works through a different channel than GLP-1 drugs like semaglutide, it could potentially be combined with those drugs to help the many patients with type 2 diabetes who still have poorly controlled blood sugar on existing treatments. This could matter for millions of people worldwide.
Does this peptide have weaker effects on immune cells than native VIP, while still protecting nerve cells?
If true, this peptide could be used to treat neurological diseases in patients who cannot afford to have their immune system weakened, including elderly patients or those on other immune-suppressing medications. This could expand who is eligible for this type of treatment.
Does this peptide form the right folded shape to activate its receptor while avoiding the membrane damage that makes similar peptides toxic?
If the peptide can activate its target receptor without disrupting cell membranes, it could be used at higher doses or for longer durations than native VIP, potentially making it effective for chronic conditions like neurodegeneration or chronic inflammatory disease where sustained treatment is needed.
Do the positively charged parts of this peptide stick to sugar-coated proteins on brain cell surfaces, concentrating it near where it needs to work?
If the peptide naturally accumulates at the right cell surfaces, it could work at lower doses than expected, reducing the risk of side effects. This would matter most for neurological treatments where getting enough drug to the brain while limiting body-wide exposure is a key challenge.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| IC50 | 0.11 nM | GPCRDB/ChEMBL |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10469,
sequence = {HSDAVFTDNYTRLRKQLAVKKYLNSILN},
target = {vpac1},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}